Akebia Therapeutics Inc. Stock
Price
Target price
€1.02
€1.02
2.180%
0.022
2.180%
-
02.06.23 / Tradegate
WKN: A1XF0S / Symbol: AKBA / Name: Akebia / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akebia Therapeutics Inc. Stock
There is an upward development for Akebia Therapeutics Inc. compared to yesterday, with an increase of €0.022 (2.180%).
Our community identified positive and negative aspects for Akebia Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Akebia Therapeutics Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Akebia Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
B****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akebia Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akebia Therapeutics Inc. | 2.180% | -2.476% | 28.000% | 208.434% | 119.366% | -89.961% | - |
| Brainstorm Cell | -0.720% | -0.725% | -0.725% | 1.182% | 93.230% | -61.135% | - |
| Sorrento Therapeutics Inc. | -24.520% | 0.000% | 0.000% | -82.438% | -65.296% | -93.513% | - |
| Concert Pharmaceuticals Inc. | 0.180% | 0.000% | 0.000% | - | 56.305% | - | - |
Comments
Akebia Therapeutics, Inc. (NASDAQ: AKBA) was upgraded by analysts at Piper Sandler from a "neutral" rating to an "overweight" rating.
Show more
Ratings data for AKBA provided by MarketBeat
News
Why Shares of Akebia Therapeutics Were Up Tuesday
Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight
